Advertisement

Topics

ArQule nets $9.3mm through preferred stock sale

14:40 EST 9 Nov 2017 | Elsevier Business Intelligence

In its second private placement in two months, cancer and rare disease drug developer ArQule Inc. netted $9.3mm through the s...

Original Article: ArQule nets $9.3mm through preferred stock sale

NEXT ARTICLE

More From BioPortfolio on "ArQule nets $9.3mm through preferred stock sale"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...